Maintains Strong Growth Amid Global Health Focus
SIGA Technologies Posts Q2 2024 Earnings, Maintains Strong Growth Amid Global Health Focus
SIGA Technologies, Inc. (NASDAQ: SIGA) reported solid financial results for Q2 2024. The company posted revenue of $21.81 million, largely driven by sales of its flagship product, TPOXX®, an antiviral medication used for smallpox and mpox (monkeypox). Earnings per share (EPS) came in at $0.03, exceeding analyst expectations.
Financial and Market Performance
• Revenue: $21.81 million, showing steady product sales.
• EPS: $0.03, beating forecasts.
• Stock Performance: The stock is trading around $10.13, up significantly year-to-date, with a strong P/E ratio of 9.49 .
Future Outlook
Analysts forecast earnings growth of 23.76% over the next year, with EPS expected to rise to $1.25 in 2025. SIGA’s focus on infectious disease treatments and government contracts positions it well for continued growth.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
SIGA Technologies, Inc. (NASDAQ: SIGA) reported solid financial results for Q2 2024. The company posted revenue of $21.81 million, largely driven by sales of its flagship product, TPOXX®, an antiviral medication used for smallpox and mpox (monkeypox). Earnings per share (EPS) came in at $0.03, exceeding analyst expectations.
Financial and Market Performance
• Revenue: $21.81 million, showing steady product sales.
• EPS: $0.03, beating forecasts.
• Stock Performance: The stock is trading around $10.13, up significantly year-to-date, with a strong P/E ratio of 9.49 .
Future Outlook
Analysts forecast earnings growth of 23.76% over the next year, with EPS expected to rise to $1.25 in 2025. SIGA’s focus on infectious disease treatments and government contracts positions it well for continued growth.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.